Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Rybelsus related dizziness can stem from its effects on stomach emptying, blood pressure, blood sugar and hydration. Most mild to moderate cases improve with simple adjustments like eating small meals, staying hydrated and rising slowly, but persistent or severe symptoms may warrant a discussion about switching medications.
There are several factors to consider, so see below for detailed explanations and guidance on preparing to talk with your provider.
Dizziness is a common concern for people taking Rybelsus (semaglutide), a once-daily oral medication prescribed for type 2 diabetes. If you've ever wondered why does Rybelsus cause dizziness and what you can do about it, you're not alone. This article explains the science behind Rybelsus-related dizziness, outlines practical management tips, and helps you decide whether switching medications might be appropriate for you.
Rybelsus is an oral glucagon-like peptide-1 (GLP-1) receptor agonist. It works by:
By targeting multiple pathways, Rybelsus helps improve blood glucose levels and can reduce A1C values. However, like many effective therapies, it may produce side effects—including dizziness.
Understanding why does Rybelsus cause dizziness involves looking at several physiological effects:
Delayed Gastric Emptying
Changes in Blood Pressure
Blood Sugar Fluctuations
Dehydration and Electrolyte Shifts
Clinical trial data and post-marketing reports suggest:
While uncomfortable, dizziness typically improves over several days to weeks as your body adjusts. Persistent or severe dizziness may warrant further evaluation.
Certain factors increase the likelihood of Rybelsus-related dizziness:
Most cases of dizziness can be managed without stopping your medication. Try these strategies:
While most dizziness episodes improve with the strategies above, you should consider discussing a medication change if you experience:
Your healthcare provider can evaluate whether another GLP-1 receptor agonist (injectable or oral) or a different class of diabetes medication might be better suited to your needs.
Gather Your Data
List Your Concerns
Ask Specific Questions
Discuss a Transition Plan
If you're experiencing dizziness or other concerning symptoms on Rybelsus, taking proactive steps can help:
Above all, never ignore severe or life-threatening symptoms. If you experience chest pain, fainting, severe dehydration, or persistent vomiting, seek immediate medical attention.
Dizziness on Rybelsus can stem from its effects on gastric emptying, blood pressure, blood sugar, and hydration status. For most people, simple adjustments—like eating small meals, staying hydrated, and rising slowly—can resolve mild to moderate symptoms. If dizziness persists or significantly impacts your daily life, talk to your doctor about changing medications.
Your health and safety come first. Always consult your healthcare provider before making any changes to your treatment plan, and use online tools responsibly to guide your next steps.
Speak to a doctor if you have any serious or concerning symptoms—your provider can help you find the best approach to managing diabetes without compromising your quality of life.
(References)
* Husain M, Bain SC, Holst AG, Kissell T, Pettersson J, Woo V. Safety, tolerability, and efficacy of oral semaglutide in patients with type 2 diabetes: a narrative review. Diabetes Ther. 2023 Feb;14(2):291-314. doi: 10.1007/s13300-022-01348-1. Epub 2023 Jan 2. PMID: 36592237.
* Sun M, Wu M, Lin Z, Wu J, Zhang D, Zhao H, Li J. Efficacy and Safety of Oral Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis. J Clin Pharmacol. 2020 Jan;60(1):8-18. doi: 10.1002/jcph.1517. Epub 2019 Sep 3. PMID: 31478206.
* Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Schwenke S, Škrha J, Velho G, Webb N, Brath H, Warren ML; PIONEER 6 Investigators. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019 Aug 29;381(9):841-851. doi: 10.1056/NEJMoa1901118. Epub 2019 Jun 11. PMID: 31185150.
* Mosenzon O, Blicher P, Brath H, Eliaschewitz FG, Franco DR, Jeppesen OK, Kaltoft K, Lingvay I, Ocampo-Lim B, Schwenke S, Thomsen M, Warren ML; PIONEER 5 Investigators. Once-Daily Oral Semaglutide in Patients with Type 2 Diabetes and Moderate Renal Impairment (PIONEER 5): A Placebo-Controlled, Randomised, Phase 3a Trial. Lancet Diabetes Endocrinol. 2019 Jul;7(7):515-527. doi: 10.1016/S2213-8587(19)30191-3. Epub 2019 May 22. PMID: 31128916.
* Rodbard HW, Rosenstock J, Sugimoto D, Araki E, Zarotsky V, Thomsen M, Toulis KA, Lee C; PIONEER 2 Investigators. Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin: The PIONEER 2 Trial. Diabetes Care. 2019 Dec;42(12):2272-2281. doi: 10.2337/dc19-0877. Epub 2019 Sep 25. PMID: 31551390.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.